Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05105009
Other study ID # 19-1131
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 3, 2020
Est. completion date July 1, 2022

Study information

Verified date October 2021
Source Instituto Nacional de Cardiologia Ignacio Chavez
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two phase study. The first part will take place at the National Institute of Cardiology in Mexico, the second phase will be made in collaboration with the University of California San Diego. This is a non blind experimental study, 60 patients with different stages of CKD from the outpatient unit of the institute will be included. Each patient will receive a furosemide stress test of 1 mg/kg in non diuretic users and 1.5 mg/kg in diuretic users, in addition to an oral load of 5 grams of creatinine, as well as Iohexol to measure GFR. After the intervention blood and urine samples will be drawn at 10 minutes, 30 minutes, and every hour until the completion of the observation at 6 hours. Blood and urine will be analized to measure creatinine (blood and urine), then samples will be processed for measurement of furosemide (mass spectometry), indoxyl sulphate, p-cresol, hippurate, and uromoduline. The aim of this stiudy is to asses the differences between GFR and proximal tubule function.


Description:

Residual kidney function (RKF) its a critical tool in the CKD evolution and prognosis. It's well known that preserving RKF increases survival in patients with CKD. Traditionally Glomerular Filtration Rate (GFR), and proteinuria have been the variables used to asses RKF, wich are glomerular residual function (GRF) variables. This glomerulocentric assestment of RKF has been challenged recently. It is knows that urea is not the principal uremic toxine, the protein boud uremic toxins are particullary important because it's elimination depends of the proximal tubular organic anionic transporters (OAT), and the organic cationic transporters (OCT). The functional integrity of this transporters are lost in advanced CKD stages, and it´s accumulation increases cardiovascular and renal damage because they activate proinflammatory citokines, increasing mortality, this was shown specially with the accumulation and clearance of hippurate and p-cresol independently of GFR. The purpose of this study is to asses the functional capacity of two AOT (hOAT1, and hOAT3, that can be blocked by furosemide), and one OCT (OCT2 blocked by creatinine) using an stress test. The stress test will be performed in healthy subjects as well as in CKD from different stages. Protein bound uremic toxins such as indoxyl sulphate, p-cresol, and hippurate will be measured. In the stress the typical furosemide stress test described previously by Mehta will be implemented, in addition to an oral load of 5 grams of creatinine oral load. This levels should be efficient enough to assess the functionality of the OCT2. A comparison between the tubular creatinine secretine to filtrated creatinine measuring GFR using Iohexol will be performed. In conclusion this is a pilot study aimed to establish a practical methodology for the assesment of proximal tubular function.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date July 1, 2022
Est. primary completion date December 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients older than 18 years old. - Patients with CKD that attends to the outpatient clinic. - Residual uresis of 500 mL Exclusion Criteria: - Patients younger than 18 years old. - Increase of Cr in a rate of 0.5 mg/dL, or loss of more than 30% of previous GFR. - Patients with cardiorrenal syndrome type 1. - Patients with dilated miocardiopathy. - Volume overload.

Study Design


Intervention

Drug:
Furosemide
Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users). Oral creatinine load using 5 grams of creatinine

Locations

Country Name City State
Mexico Instituto Nacional de Cardiologia Ignacio Chávez Mexico City

Sponsors (1)

Lead Sponsor Collaborator
Instituto Nacional de Cardiologia Ignacio Chavez

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tubular Residual Kidney Function To assess the functionallity of the HOAT1 and 3, as well OCT2 by stress test using furosemide and creatinine loads 1 year
See also
  Status Clinical Trial Phase
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT00806130 - Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients
Completed NCT00781690 - Reduction of Heparin Dose in Dialysis With Evodial System N/A
Completed NCT00153621 - Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients N/A
Completed NCT06165211 - Nature-Based Sound Application For Hemodialysis Patients N/A
Not yet recruiting NCT04013620 - CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction Phase 3
Withdrawn NCT03998917 - Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
Completed NCT02586376 - Effects of the Low-level Laser Therapy (LLLT) on Muscle Strength (MS) of the Patients With Kidneys Failure (KF) N/A
Completed NCT00794326 - Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD Phase 3
Completed NCT05185999 - Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients Phase 1
Completed NCT03076528 - An Innovative Virtually Supervised Exercise for Dialysis Patients Phase 2
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Unknown status NCT00788905 - Comparison of Conventional Dialysis and the Allient System N/A
Completed NCT00804453 - Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line N/A
Completed NCT01085552 - Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects Phase 1
Completed NCT00694824 - Vascular Calcification's Risk Factors in Haemodialysis Patients
Completed NCT00074620 - A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis Phase 2
Withdrawn NCT06030050 - Animal Assisted Intervention for Hemodialysis Outpatients N/A
Recruiting NCT05562869 - Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction Phase 3
Completed NCT03437538 - Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter N/A